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A B S T R A C T
Obesity and insulin resistance is a common finding in patients with polycystic ovary syndrome (PCOS). Significant
number of PCOS women experience insulin resistance that is irrespective of the degree of obesity suggesting possible ge-
netic basis. Therefore, several polymorphisms of the genes encoding for the insulin (INS), insulin receptor (INSR) or in-
sulin receptor substrates (IRS) involved in postreceptor signaling have been explored for their association with abnormal
sensitivity to insulin in PCOS. The aim of the present study was to determine whether selected polymorphisms of INS,
INSR and IRS-1 are associated with the development of PCOS as well as with increased insulin resistance in Croatian
women with PCOS. The study enrolled 150 women with PCOS and 175 control women. The diagnosis of PCOS was
based on Rotterdam consensus criteria. Each subject underwent an evaluation of body mass index (BMI), hirsutism,
acne and menstrual cycle abnormalities as well as follicular stimulating hormone (FSH), luteinizing hormone (LH), to-
tal and free testosterone, androstendione, dehydroepiandrosterone sulphate (DHEAS), sex hormone binding globulin
(SHBG), fasting glucose and fasting insulin. Insulin resistance (IR) was quantified using the homeostatic model assess-
ment of IR (HOMA-IR). Molecular analyses for the genetic polymorphisms were preformed. There was a significant dif-
ference in clinical and biochemical characteristics of the studied groups except for BMI and fasting glucose levels. No
significant differences were observed in the genotype and allele distribution of the VNTR INS, C/T INSR, Gly792Arg
IRS-1 polymorphisms between cases and controls. Moreover, no association was found between VNTR INS, C/T INSR
and Gly792Arg IRS-1 polymorphism and parameters of insulin resistance in PCOS patients. In conclusion, our data
does not support an association between VNTR INS, C/T INSR and Gly792Arg IRS-1 polymorphism and susceptibility
to PCOS or insulin resistance in Croatian women with PCOS.
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Introduction
Obesity and insulin resistance is a common finding in
patients with PCOS. The mechanism that induces insu-
lin resistance in PCOS is not fully understood1,2. Signifi-
cant number of PCOS women experience insulin resis-
tance that is irrespective of the degree of obesity sug-
gesting possible genetic basis. Therefore, several poly-
morphisms of the genes encoding for the insulin (INS),
insulin receptor (INSR) or insulin receptor substrates
(IRS) involved in postreceptor signaling have been ex-
plored for their association with abnormal sensitivity to
insulin in PCOS3–5.
Variable number tandem repeat (VNTR) is a minisa-
tellite element which lies 5’ to the insulin gene (INS)6,7.
This highly polymorphic locus modifies insulin transcrip-
tion in vitro therefore may contribute to altered insulin
secretion in PCOS patients8. Waterworth et al. were first
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to report that the PCOS phenotypes were associated
with the category III alleles at the INS VNTR-locus9 but
subsequent studies in women with PCOS from other eth-
nic backgrounds produced conflicting and inconsistent
results10–15. There is also evidence that the interaction of
obesity and the III/III INS VNTR genotype might be a
risk factor for the development of PCOS10.
Insulin receptor gene (INSR) is composed of 22 exons.
The tyrosine kinase domain mutations (exons 17–21) are
associated with severe insulin resistance and hyperin-
sulinemia16. Several studies reported that the common
polymorphism involving substitution of C to T in the
INSR gene (His-1058 C / T in exon 17) is associated with
PCOS especially in interaction with BMI3,17–20.
Insulin receptor substrate-1 (IRS-1) is the first sub-
strate in the insulin signaling pathway21. The most com-
mon IRS-1 polymorphic variant, a Gly to Arg change at
codon 972 (G972A) modifies and impairs insulin-stimu-
lated signals contributing to insulin resistance3,22–24. The
association between this polymorphism and the risk of
PCOS has been observed in studies from different ethnic
backgrounds3,4. There is also evidence that PCOS pa-
tients with Gly792Arg – polymorphism have a higher
BMI, higher insulin resistance and elevated fasting insu-
lin compared with patients with normal BMI and match-
ed controls22,24,25.
The aim of the present study was to determine whe-
ther selected polymorphisms of INS, INSR and IRS-1 are
associated with the development of PCOS as well as with
increased insulin resistance in Croatian women with
PCOS.
Subjects and Methods
Subjects
A total of 150 PCOS patients were enrolled in the
study with mean age of 26.7±5.9 (mean ± SD). The co-
hort was published in part previously26. The diagnosis of
PCOS was made according to the Rotterdam consensus
criteria, which are based on the presence of two out of
three traits including oligo- and/or anovulation, clinical
and/or biochemical signs of hyperandrogenism, and poly-
cystic ovaries on ultrasound scanning27. The menstrual
irregularities were defined as the presence of amenorr-
hea or oligomenorrhea. Hyperandrogenism was assessed
by the presence of hirsutism and/or acne and/or by ele-
vated androgen levels (serum total testosterone (TT)>
2.5 nmol/L or free testosterone (FT)>30 pmol/L). Hir-
sutism was defined by Ferriman-Gallwey index score>8
(FG>8)28. Other endocrinopathies and related disorders
were ruled out by measuring basal serum 17-hydroxypro-
gesterone (17-OHP), prolactin (PRL) and thyroid stimu-
lated hormone (TSH) levels.
The control group consisted of 175 healthy volunteers
aged 29.1±4.7 years before entering in vitro fertilisation
(IVF) programme due to male factor infertility. They had
no menstrual cycle irregularities, no clinical or biochemi-
cal hyperandrogenism, no PCO findings on ultrasound,
no history of endocrinological or autoimmune disorders
and no surgery to the pelvic region. The patients discon-
tinued medication (including hormonal contraceptives)
for at least six months prior to enrolment to study.
All patients were observed in the early follicular pha-
se of the menstrual cycle (day 3–5) or randomly in
amenorrhoeic patients. The body mass index (BMI) was
calculated as weight/height2 (kg/m2). Transvaginal ultra-
sound (TVUS) was done to diagnose PCO according to
the Rotterdam criteria27. Blood samples were drawn for
the measurement of luteinizing hormone (LH), follicle
stimulating hormone (FSH), total testosterone (TT), sex
hormone binding globulin (SHBG), dehydroepiandroste-
rone sulphate (DHEAS), androstendione (A), fasting se-
rum glucose and fasting insulin. Free testosterone (FT)
was calculated from TT and SHBG as previously publi-
shed29 using a web-based calculator (http://www.issam.
ch/freetesto.htm). Insulin resistance (IR) was quantified
using the homeostatic model assessment of IR (HOMA-
-IR) (fasting insulin (mU/L) x fasting glucose (mmol/L)) /
22.5). Whole blood samples were obtained for genetic
analysis.
The study protocol No. 04-1116-2006 was approved by
the University of Zagreb Medical School Ethics Commit-
tee. Informed written consent was obtained from all
women enrolled in the study.
Biochemical Analysis
Serum LH, FSH, SHBG, TT, DHEAS and A levels
were measured. Serum LH, FSH, and TT concentrations
were determined by chemiluminescent immunometric
assays using LH – Vitros, FSH – Vitros, and Testosterone
– Vitros, respectively (Ortho Clinical Diagnostics, John-
son&Johnson, Rochester, NY, USA). Serum SHBG, DHEAS
and A levels were measured using chemiluminescent
immunometric assays (SHBG – Immulite, DHEAS – Im-
mulite and Androstendione-Immulite, respectively) (Sie-
mens Healthcare Diagnostics Inc., Deerfield, IL, USA). The
intra-assay and inter-assay coefficients of variation ran-
ged between 1.5 and 7.9%. The plasma glucose level (Glc)
was determined by the UV-photometric hexokinase me-
thod and the serum insulin (Ins) level by chemilumi-
nescent immunometric assay using Insulin-Immulite, re-
spectively (Siemens Healthcare Diagnostics Inc., Deerfield,
IL, USA).
Genomic DNA was isolated from whole blood using
FlexiGene Kit (Qiagen GmbH, Hilden, Germany) follow-
ing the manufacturer´s protocol. Genotyping for
rs1801278 (Gly972Arg in the IRS1 gene) and rs1799817
(C10923T in the INSR gene) was performed with real-
-time PCR allelic discrimination on 7900HT system us-
ing C__2384392_20 and C__8356128_1_assays, respec-
tively (Applied Biosystems, Foster City, CA) following the
manufacturer´s protocol. Genotyping of the INS VNTR
was performed indirectly by analysing its surrogate mar-
ker, the –23HphI A>T polymorphism of the INS gene. In
Europeans, the –23 T alleles have been found to be in
complete linkage disequilibrium with INS VNTR class I
alleles and the –23 A alleles have been found to be in
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complete linkage disequilibrium with INS VNTR class
III alleles30. The appropriate Custom TaqMan® SNP
Genotyping Assay (Applied Biosystems, Foster City, CA)
was used, containing unlabelled target-specific primers
(F: 5´-GGG CAC CTG GCC TTC AG-3´, R: 5´-CCA TGG
CAG AAG GAC AGT GA-3´), TaqMan® MGB VIC dye-la-
belled probe for detection of HphI T alleles (5´-CCT GCC
TGT CTC CCA GA-3´) and TaqMan® MGB 6-FAM dye-
-labelled probe for detection of HphI A alleles 5´-CTG
CCT GTC ACC CAG A-3´.
Genotype analysis was conducted at the Department
of Obstetrics and Gynaecology, Division of Medical Ge-
netics, University Medical Centre Ljubljana.
Statistical Analysis
In a comparison of the clinical and hormonal parame-
ters the categorical variables were described by percent-
ages, and the continuous as mean ± standard deviation.
We used the independent Student’s t-test to compare the
values of the means between cases and controls, while dif-
ferences in categorical characteristics were assessed using
c2-test. Statistical analysis of the differences in genotype
frequencies was performed using c2-test. Differences in
clinical and biochemical parameters according to the ge-
notype of the PCOS patients were assessed using the
Mann-Whitney U test or Kruskal-Wallis test for the con-
tinuous, and c2-test for the categorical variables. Results
were described as medians (interquartile ranges) or per-
centages. All statistical analysis were done using the SPSS
for Windows (version 15.0; SPSS Inc., Chicago, IL, USA).
A p-value<0.05 was considered statistically significant.
Results
Clinical and biochemical characteristics
of patients
The clinical and hormonal characteristics of the groups
studied are presented in the Table 1. As expected accord-
ing to Rotterdam consensus criteria PCOS patients pre-
sented with higher mean serum levels of LH, TT, FT and
HOMA–IR, whereas the mean serum SHBG and FSH
levels were significantly lower than in the control group.
The PCOS patients had higher BMI, and a significantly
higher frequency of hirsutism than controls. (Table 1)
Allelic and genotypic frequencies of INS VNTR,
INSR His 1058 C/T and IRS-1 Gyl972Arg
polymorphisms in PCOS patients and controls
The allele and genotype distributions of the INS
VNTR, INSR His 1058 C/T and IRS-1 Gyl972Arg poly-
morphism for both PCOS and control group were consis-
tent with the Hardy-Weinberg equilibrium and are pre-
sented in Table 2.
We found no significant difference in the distribution
of category III INS-VNTR and category I INS-VNTR al-
leles between the groups studied (p=0.325, Table 2). Cat-
egory II INS-VNTR allele was not present in our studied
population. Patients with PCOS were frequent carriers
of homozygous category III INS-VNTR genotype com-
pared to the control group; however, this difference was
not significant (Table 2).
Frequency distribution of T allele, and C allele of the
INSR His 1058 C/T polymorphism was not different be-
tween the groups investigated (p=0.810, Table 2). There
was also similar distribution of different genotypes be-
tween the groups, although the C/C genotype presented
more frequently in the control group. Because of the low
frequency of T/T genotype, for further analysis we di-
vided the genotypes into two categories: C/C and C/T+ T/T.
The Arg allele of the IRS-1 Gyl972Arg polymorphism
was frequently more present in the control group com-
pared to PCOS group, but this finding was not significant
(p=0.186, Table 2). The distribution of various alleles and
genotypes was comparable between the groups as it is pre-
sented in Table 2. Because of the low frequency of Arg/Arg
genotype, for further analysis we divided the genotypes
into two groups: Gly/Gly and Gly/Arg+Arg/ Arg.
Influence of INS VNTR, INSR His 1058 C/T and
IRS-1 Gyl972Arg polymorphisms on BMI, fasting
insulin and HOMA-IR levels
We found no significant influence of INS VNTR,
INSR His 1058 C/T and IRS-1 Gyl972Arg genotype con-
cerning BMI, fasting serum insulin levels and insulin
sensitivity in our studied group of PCOS patients as indi-
cated in Table 3.
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TABLE 1
COMPARISON OF CLINICAL AND HORMONAL PARAMETERS IN
THE PCOS AND CONTROL PATIENTS
PCOS
(N=150)
Control
(N=175)
p-value1
Age (years) 26.7±5.9 29.1±4.7 0.001
BMI (kg/m2) 23.4±4.2 22.4±3.3 0.019
BMI<25 (kg/m2) (%) 77.0 89.3 0.004
FSH (IU/L) 3.9±1.9 5.1±1.4 <0.001
LH (IU/L) 8.9±5.9 3.2±1.2 <0.001
TT (nmol/L) 2.3±0.9 1.2±0.4 <0.001
FT (pmol/L) 42.6±23.2 14.7±6.3 <0.001
A (nmol/L) 11.1±4.9 7.1±3.8 <0.001
DHEAS (mmol/L) 6.5±2.7 4.9±1.9 <0.001
SHBG (nmol/L) 35.9±21.5 53.9±33.8 <0.001
HOMA-IR 2.3±2.8 1.3±0.5 <0.001
HOMA-IR > 2.5 22.4 2.8 <0.001
Oligo/amenorrhea (%) 90.1 0.0 <0.001
Hirsutism (%) 74.8 12.8 <0.001
Acne (%) 52.3 19.3 <0.001
BMI: body mass index; FSH: follicle stimulating hormone; LH:
luteinizing hormone; TT: total testosterone; FT: free testoster-
one; A: androstendione; DHEAS: dehydroepiandrosterone sul-
phate; SHBG: sex hormone binding globulin; HOMA-IR: ho-
meostatic model assessment of insulin resistance
1 Students’ t-test was used for continuous and c2-test for cate-
gorical variables
Discussion and Conclusion
The association of the INS VNTR, the INSR His 1058
C/T and the IRS-1 Gyl972Arg polymorphisms with
PCOS have been studied in different populations but the
results observed are conflicting and inconsistent3,4,7,10–15,
17,18,20–25,30. To our knowledge this is the first study to ex-
plore this association in Croatian population of women
with PCOS.
The PCOS patients tended to have a higher frequency
of homozygous category III INS VNTR alleles compared
to controls, although allele distribution was not signifi-
cantly different between the groups, indicating that the
VNTR INS polymorphism is not the major determinant
of the PCOS (Table 1). This is concurrent with the obser-
vation of some previous studies in the Czech, Spanish,
English, Finish and Chinese population with PCOS1,11–13.
Additionally, we assessed the influence of INS VNTR
polymorphism on insulin resistance in the PCOS and
control group but found no significant association. This
is in agreement with findings of Vankova et al. in Czech
patients with PCOS13. Altered insulin sensitivity is prob-
ably the result of simultaneous interaction of different
environmental and genetic factors31–36. Ferk et al. ob-
served that the interaction of INS VNTR genotype with
obesity might be a risk factor for the development of
PCOS in Slovenian PCOS patients10. This interaction
was not confirmed in our study however our results may
have been biased by a small number of patients with
BMI>25 kg/m2.
We observed significantly lower frequency of T allele,
and homozygous T/T genotype than previously repor-
ted3. The distribution of the polymorphic His 1058 C/T
INSR alleles was equivalent between PCOS and the con-
trol group therefore we assume that this polymorphism
is not significantly associated with the development of
PCOS in Croatian PCOS patients. This is in agreement
with the findings of two previous published studies in
Turkish and Korean population19,37. The positive associa-
tion between this polymorphism and PCOS was fre-
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TABLE 2
GENOTYPE DISTRIBUTION OF INS VNTR, INSR HIS 1058 C/T
AND IRS-1 GYL972ARG POLYMORPHISMS IN THE PCOS
PATIENTS AND CONTROLS
Gene Genotype
PCOS
N=150
Controls
N=170
p1
VNTR
III/III 55.1% 50.2% 0.561
I/III 38.8% 42.1%
I/I 6.1% 7.7%
Allele frequency
III alleles (2N) 74.5% 71.3% 0.325
I alleles (2N) 25.5% 28.7%
INS
C/C 63.2% 65.9% 0.631
C/T 34.2% 30.2%
T/T 2.6% 3.9%
Allele frequency
C allele (2N) 80.3% 81.0% 0.810
T allele (2N) 19.7% 19.0%
IRS-1
Gly/Gly 87.5% 83.6% 0.506
Gly/Arg 11.8% 14.7%
Arg/Arg 0.7% 1.7%
Allele frequency
Gly allele (2N) 93.7% 91.0% 0.186
Arg allele (2N) 6.3% 9.0%
1 c2-test
TABLE 3
BMI, INSULIN AND HOMA-IR VALUES ACCORDING TO INS VNTR, INSR HIS 1058 C/T AND IRS-1 GYL972ARG GENOTYPE IN
THE PCOS PATIENTS
INS VNTR
genotype
p1
INSR His 1058 C/T
genotype
p2
IRS-1 Gyl972Arg
genotype
p2
III/III
N=83
I/III
N=58
I/I
N=9
C/C
N=95
C/T+T/T
N=55
Gly/Gly
N=132
Gly/Arg +
Arg/Arg
N=18
BMI (kg/m2)
22.2
(20.9–24.1)
22.1
(20.7–24.7)
23.6
(21.5–24.8)
0.712
22.4
(21.0–25.2)
21.9
(20.9–24.5)
0.614
22.4
(21.0–24.8)
21.8
(20.7–24.8)
0.315
BMI >25 (kg/m2) (%) 18.6 22.9 23.1 0.744 26.0 17.9 0.319 21.1 15.8 0.423
Fasting insulin
(mIU/L)
8.9
(7.4–10.9)
8.7
(6.2–11.8)
8.2
(6.7–9.7)
0.916
8.6
(6.1–13.3)
8,8
(7.1–10.4)
0.966
8.7
(6.2–11,7)
9.0
(5.7–11.4)
0.800
HOMA-IR
1.7
(1.3–2.5)
1.6
(1.1–2.3)
1.5
(1.2–1.9)
0.894
1.6
(1.0–2.5)
1.7
(1.2–2.2)
0.953
1.7
(1.1–2.3)
1.7
(1.2–2.3)
0.861
HOMA-IR >2.5 (%) 19.7 25.8 20.0 0.680 26.0 16.1 0.166 22.6 21.1 0.883
BMI: body mass index; HOMA – IR: homeostatic model assessment of insulin resistance; 1 Kruskal-Wallis test continuous variables,
c2-test categorical variable; 2 Mann–Whitney U test continuous variables, c2 -test categorical variable
quently observed in lean PCOS patients17,20,21. Siegel et
al.21 reported higher frequency of T allele in PCOS pa-
tients with BMI <27 kg/m2 while Chen et al. confirmed
these results in lean PCOS patients from China17. The
major limitation of these two studies is lack of informa-
tion on association of this polymorphism with insulin re-
sistance while altered insulin sensitivity is considered to
have strong genetic origin in lean PCOS patients31. Muk-
herjee et al. found preferential expression of C/T INSR
genotype in lean group of PCOS patients from India
(BMI < 23 kg/m2)20. Carriers of this polymorphism also
presented with higher values of fasting insulin and
HOMA-IR20. Although women with PCOS in our studied
group were generally lean we recorded no association of
C/T-INSR gene polymorphism with parameters of insulin
resistance.
We observed no significant difference in the distribu-
tion of Gly972Arg IRS-1 alleles between PCOS group
and controls. This is concurrent with observations repor-
ted from Chilean, Spanish and Taiwan population25,38,39.
Previously conducted studies also reported that insu-
lin-resistant women with PCOS are frequently carriers
of polymorphic Arg allele which directs to conclusion
that this polymorphism may be associated with the de-
velopment of insulin resistance in PCOS22,24,25,39. In con-
trast to these observations we found higher frequency of
Arg allele in the control group however overall frequency
of this polymorphic allele was very low. The results of
aforementioned studies were included in a recently pub-
lished metaanalysis of Ioannidis et al. that cumulatively
confirmed the considerable association of IRS-1 polymor-
phism with the risk of developing PCOS but this associa-
tion is primarily mediated by increasing the levels of fast-
ing insulin3. We found no difference in fasting serum in-
sulin levels between the carriers of different Gly872Arg
genotypes. This may be the result of a very low incidence
of this polymorphism in our population studied.
In conclusion, the VNTR INS, C/T INSR,Gly792Arg
IRS-1 polymorphisms are not likely candidates for PCOS
development in Croatian population. Moreover, these
polymorphisms are not associated with increased param-
eters of insulin resistance in women with PCOS.
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POLIMORFIZMI GENA ZA INS, INSR I IRS-1 NISU POVEZANI SA SINDROMOM POLICISTI^NIH
JAJNIKA U HRVATSKOJ POPULACIJI PCOS BOLESNICA
S A @ E T A K
Povi{ena tjelesna te`ina i inzulinska rezistencija ~esto su udru`eni sa sindromom policisti~nih jajnika. Velik broj
bolesnica s PCOS-om ima inzulinsku rezistenciju neovisno o povi{enoj tjelesnoj te`ini {to govori u prilog genskoj uvjeto-
vanosti. Do sada je istra`ivana genska podloga u polimorfizmima gena koji kodiraju za inzulin (INS), inzulinski receptor
(INSR), ali i gena za inzulinske receptorske supstrate (IRS) koji imaju klju~nu ulogu u usmjeravanju postreceptorskog
signala. Istra`ivana je njihova povezanost sa inzulinskom rezistencijom kod PCOS bolesnica. Cilj ovog istra`ivanja bio
je istra`iti povezanost genskih polimorfizama: VNTR INS, C/T INSR, Gly792Arg i IRS-1 sa nastankom PCOS-a te sa
parametrima inzulinske rezistencije u hrvatskoj populaciji bolesnica s PCOS-om. U studiju smo uklju~ili 150 PCOS
bolesnica i 175 kontrola. Dijagnozu smo postavili na temelju konsenzusa u Rotterdamu. Svakoj ispitanici izmjeren je
ITM, stupanj hirzutizma i akni te ocijenjen poreme}aj ciklusa. Odre|ene su serumske vrijednosti FSH, LH, ukupnog i
slobodnog testosterona, DHEAS-a, androstendiona, SHBG-a te glukoze i inzulina na ta{te. Inzulinska rezistencija izra-
~unana je koriste}i HOMA-IR (homeostatic model assessment of IR). Provedene su molekularne genske analize za
odre|ivanje genskih polimorfizama. Na{li smo zna~ajnu razliku u ve}ini klini~kih i biokemijskih karakteristika izme|u
istra`ivanih skupina osim za ITM i glukoze na ta{te. Nismo na{li zna~ajnu razliku u raspodjeli alela i genotipova poli-
morfizama VNTR INS, C/T INSR i Gly792Arg IRS-1 izme|u istra`ivane i kontrolne skupine kao niti utjecaj navedenih
polimorfizama na parametre inzulinske rezistencije u PCOS bolesnica. U zaklju~ku, na{i rezultati ne podupiru ranije
opisanu povezanost VNTR INS, C/T INSR i Gly792Arg IRS-1 sa razvojem PCOS-a odnosno sa inzulinskom rezisten-
cijom u Hrvatskoj populaciji bolesnica sa PCOS-om.
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